ArticleNano letters2023
Cellular Delivery of Large Functional Proteins and Protein-Nucleic Acid Constructs via Localized Electroporation.
Article in Nano letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Protein Modifications for Cellular Protein Delivery.Chemical reviews · 2026Review
- An integrated nanopore-microfluidic platform for low-voltage electroporation of delivering self-amplifying RNA into dendritic cells.Microsystems & nanoengineering · 2026Article
- Biomaterial-Integrated Electroporation for Therapeutic Delivery: From Gene Editing to Tumor Ablation and Immune Modulation.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Nanopore Electroporation: A New Delivery Method Within the Field of Epigenetic Editing.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Regulation of Pore Evolution via Progressive Electroporation Enhanced Intracellular Molecule Transport.Research (Washington, D.C.) · 2026Article
- Microfluidic Electroporation: Recent Advances and Applications.Advances in experimental medicine and biology · 2026Review
- Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Efficient Direct Cytosolic Protein Delivery via Protein-Linker Co-engineering.ACS applied materials & interfaces · 2025Article
- Mechanistic Insights into the Tools for Intracellular Protein Delivery.Chem & bio engineering · 2025Review
- Mechanically mediated cargo delivery to cells using microfluidic devices.Biomicrofluidics · 2024Article
- A small-molecule carrier for the intracellular delivery of a membrane-impermeable protein with retained bioactivity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Quantitative analysis of electroporation-mediated intracellular delivery via bioorthogonal luminescent reaction.Communications chemistry · 2024Article
- Well Plate-Based Localized Electroporation Workflow for Rapid Optimization of Intracellular Delivery.Bio-protocol · 2024Article
- Analysis of In Situ Electroporation Utilizing Induced Electric Field at a Wireless Janus Microelectrode.Micromachines · 2024Article
- Transepithelial Electrical Impedance Increase Following Porous Substrate Electroporation Enables Label-Free Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- High-throughput mechanical phenotyping and transcriptomics of single cells.Nature communications · 2024Article
- Recent Progress of Rational Modified Nanocarriers for Cytosolic Protein Delivery.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Delivery of proteins and protein-nucleic acid constructs into live cells enables a wide range of applications from gene editing to cell-based therapies and intracellular sensing. However, electroporation-based protein delivery remains challenging due to the large sizes of proteins, their low surface charge, and susceptibility to conformational changes that result in loss of function. Here, we use a nanochannel-based localized electroporation platform with multiplexing capabilities to optimize the intracellular delivery of large proteins (β-galactosidase, 472 kDa, 75.38% efficiency), protein-nucleic acid conjugates (protein spherical nucleic acids (ProSNA), 668 kDa, 80.25% efficiency), and Cas9-ribonucleoprotein complex (160 kDa, ∼60% knock-out and ∼24% knock-in) while retaining functionality post-delivery. Importantly, we delivered the largest protein to date using a localized electroporation platform and showed a nearly 2-fold improvement in gene editing efficiencies compared to previous reports. Furthermore, using confocal microscopy, we observed enhanced cytosolic delivery of ProSNAs, which may expand opportunities for detection and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.